Synnovation Therapeutics
Wilmington, United States · Founded 2021
- Headquarters
- Wilmington
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- synnovationtx.com
About
Synnovation Therapeutics is a Wilmington, Delaware-based precision medicine company founded in 2021 by a world-class medicinal chemistry team from Incyte, where the founders previously contributed to the discovery of five approved drugs including Jakafi, Olumiant, Pemazyre, Tabrecta, and Opzelura. The company develops small-molecule targeted therapies optimized for best-in-class pharmacology against highly validated oncology targets. Its lead program, SNV1521, is a CNS-penetrant PARP1 inhibitor now in a Phase I study, and its second program targets oncogenic PI3K-alpha mutations. Synnovation launched publicly in January 2024 with a $102 million Series A led by Third Rock Ventures.
Summary
Synnovation Therapeutics is a Biotech company based in Wilmington, United States, founded in 2021.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...